A California think tank and drug industry advocates penned new op-eds warning against the possible 340B impacts of President Donald Trump's Medicaid drug pricing proposal.

Drug Industry Advocates Say 340B Providers Would be Unintended Beneficiaries in Effort to Kill Trump Proposed Medicaid Pricing Proposal

May 8, 2025 Shannon Young, Associate Editor/Senior Writer Views

A California think tank, and an influential drug industry trade group that funds it, are raising concerns that President Donald [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

Drug Industry Advocates Say 340B Providers Would be Unintended Beneficiaries in Effort to Kill Trump Proposed Medicaid Pricing Proposal

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Shannon Young

Drug Industry Advocates Say 340B Providers Would be Unintended Beneficiaries in Effort to Kill Trump Proposed Medicaid Pricing Proposal

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

If you are not yet a paid subscriber, please Subscribe now.

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Shannon Young

Site Footer Live